S

SSY Group Ltd
HKEX:2005

Watchlist Manager
SSY Group Ltd
HKEX:2005
Watchlist
Price: 3.58 HKD 3.77%
Market Cap: 10.6B HKD
Have any thoughts about
SSY Group Ltd?
Write Note

SSY Group Ltd
Total Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

SSY Group Ltd
Total Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Assets CAGR 3Y CAGR 5Y CAGR 10Y
S
SSY Group Ltd
HKEX:2005
Total Assets
HK$12.5B
CAGR 3-Years
9%
CAGR 5-Years
11%
CAGR 10-Years
9%
G
Grand Pharmaceutical Group Ltd
HKEX:512
Total Assets
HK$24.9B
CAGR 3-Years
10%
CAGR 5-Years
13%
CAGR 10-Years
18%
U
United Laboratories International Holdings Ltd
HKEX:3933
Total Assets
ÂĄ22.8B
CAGR 3-Years
13%
CAGR 5-Years
8%
CAGR 10-Years
4%
Sino Biopharmaceutical Ltd
HKEX:1177
Total Assets
ÂĄ66.7B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
20%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Total Assets
HK$266.4B
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Total Assets
$1.3B
CAGR 3-Years
0%
CAGR 5-Years
21%
CAGR 10-Years
19%
No Stocks Found

SSY Group Ltd
Glance View

Market Cap
10.6B HKD
Industry
Pharmaceuticals

SSY Group Ltd. stands out as a significant player in the Chinese pharmaceutical industry, seamlessly interweaving its intricate supply chain operations with its robust manufacturing capabilities. Founded in 1994, the company has its roots in the scenic Hebei Province and has evolved into a powerful force in the realm of injectable pharmaceuticals and oral solutions. The organization primarily operates through its core segment—manufacturing and distributing intravenous infusion solutions. By leveraging cutting-edge technology and adhering to stringent quality standards, SSY Group has managed to capture a sizable share of the domestic market, ensuring a steady stream of revenue. The firm's prowess isn't limited to its pharmaceutical expertise. SSY Group's growth strategy involves a careful blend of organic expansion and strategic acquisitions, which enables it to broaden its product categories and penetrate new regional markets. By offering a wide variety of products ranging from antibiotics to anti-infection drugs, the company adeptly meets diverse healthcare needs while simultaneously driving profitability. Additionally, SSY Group bolsters its financial performance through its involvement in both research and development. By dedicating resources toward innovation, it aspires to maintain its competitive edge, producing high-value products that facilitate sustainable long-term growth. Thus, SSY Group's tightly-knit approach to blending manufacturing excellence with strategic growth initiatives paints a picture of a company adeptly navigating the challenges and opportunities of the healthcare sector.

Intrinsic Value
5.42 HKD
Undervaluation 34%
Intrinsic Value
Price
S

See Also

What is SSY Group Ltd's Total Assets?
Total Assets
12.5B HKD

Based on the financial report for Jun 30, 2024, SSY Group Ltd's Total Assets amounts to 12.5B HKD.

What is SSY Group Ltd's Total Assets growth rate?
Total Assets CAGR 10Y
9%

Over the last year, the Total Assets growth was 11%. The average annual Total Assets growth rates for SSY Group Ltd have been 9% over the past three years , 11% over the past five years , and 9% over the past ten years .

Back to Top